Antibody drug coupling new model! New company received about $100 million in financing to advance the HER2-plus solid tumor clinical trial.

Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! This article is originally created by medical Macintosh, welcome to share, and reprinted with authorization. July 3, 2020 / emedclub news / - - affected by the new epidemic, the global health and economy is facing a major crisis, but in the field of biopharmaceuticals, financing continues.recently, bolt biotherapeutics, a clinical biotechnology company, announced that it had completed the oversubscribed round C financing of US $93.5 million.bolt biotherapeutics is committed to developing its immune stimulating antibody conjugates (ISAC) platform technology to treat cancer with the power of the innate immune system.in the press release, the new round of financing will support the continuous clinical development of its leading ISAC bdc-1001, which is currently used as a monotherapy for cancer expressing HER2; and support the company boltbody Gamma Expanded treatment pipeline platform.this round of financing is led by sofinnova investments, including new investors RA capital management, surveyor capital, Rock Springs capital, samsara biocapital and Pfizer ventures, as well as existing investors novo holdings, vivo capital, pivot bioventure partners and others.solid tumor treatment strategy: isacbdc-1001 is based on the boltbody Gamma The platform immunostimulatory antibody coupling (ISAC) drug, consisting of trastuzumab, a TLR7 / 8 agonist, is currently being evaluated in solid tumor patients expressing HER2.in terms of drug form, it is a bit similar to ADC drugs, except that the molecules linked are different.bdc-1001 is the first candidate product for clinical application after bolt company was established for 5 years.a phase I / II trial will be initiated in patients with HER2 + metastatic tumors (including gastric and breast cancer), which will evaluate the antitumor activity of bdc-1001 alone or in combination with keyruda.} ISAC (photo: boltbio) in preclinical model: systemic administration of HER2 targeted ISAC (her2-isac) shows local immune activation, which can lead to strong single drug activity, host immune memory and epitope diffusion.preclinical data published in SITC 2019 showed that her2-isac showed complete and lasting regression of tumor cells resistant to trastuzumab; and the protection of immune memory on syngeneic mice that no longer expressed HER2 antigen.demonstrated a sustained and meaningful response to her2-isac and the therapeutic potential of her2-isac.in addition, Randy Schatzman, chief executive of bolt, said: "basically, it's an off the shelf therapy to make it easier for doctors to treat patients, while avoiding many of the barriers to personalized I / O therapy on the market today."ISAC mechanism Gamma The platform is composed of immune stimulating antibody conjugates (ISAC). ISAC utilizes the ability of innate immune stimulants to transform cold tumors into hot ones, thus exposing tumors to the immune system and achieving tumor regression.in fact, boltbody Gamma The antibody of ISAC partly targets the tumor cells, and the TLR agonist carried by the antibody will activate the DC cells around the tumor and kill the tumor cells by using the innate immune system of the human body.and the founder and board member of bolt, Dr. Edgar g. Engleman, is also one of the inventors of the world's first approved DC cancer vaccine, Provenge, and has rich experience and knowledge in the use of DC cells.Dr Edgar g. Engleman said: "boltbody Gamma The platform reinforces the immune system and is based on our understanding of how dendritic cells (DCS) and other myeloid cells produce effective anti-tumor immunity.Boltbody Gamma ISAC is a unique class of immunotherapy, and its function is expected to produce systemic immune memory with lasting clinical benefits."} persistent immune memory (image source: boltbio) body ™ISAC selectively targets tumors to be destroyed by the immune system.tumor associated myeloid cells engulf ISAC bound tumors and carry new tumor antigens to lymph nodes, where they mediate the activation and expansion of tumor reactive T cells.in preclinical tumor models, ISAC treatment can lead to established tumor regression and immune memory, thus preventing recurrence of tumors expressing new tumor antigens, even if they no longer express ISAC target antigens.in addition to HER2 targeted antibodies, bolt's platform technology is suitable for all kinds of antibodies expressing tumor antigens to target any type of tumor.at the same time, bolt's experimental drug can also be used in patients with tolerance to checkpoint inhibitors.bolt biotherapeutics, headquartered in the San Francisco Bay area, was founded by Dr. ed Engleman, whose platform is based on technology exclusively licensed by Stanford University.since its establishment in 2015, bolt has raised more than $170 million.bolt is committed to the development of a new immuno oncotherapy ISAC, which combines the precise targeting of antibodies with the innate immune system to develop more durable tumor immunotherapy for patients.} Dr. Edgar g. Engleman (photo: boltbio) Dr. Randall Schatzman, chief executive officer of bolt, said: "we have established a strong team with expertise in key drug development areas, and this round of financing will enable us to rapidly advance the ongoing clinical research and pipeline development work.bolt technology has the potential to greatly improve our treatment methods and prospects for some cancers.persistent response to patients.in addition to bdc-1001, we are expected to nominate the next clinical candidate later this year."focusing on four popular biomedical fields, such as tumor immunity, new antibodies, stem cell regenerative medicine and gene therapy, the 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Culture Center, China, on July 19-21, 2020! Click the picture above to view the agenda of the conference